Please login to the form below

Not currently logged in
Email:
Password:

Another setback for Teva's laquinimod in MS

Side effects seen in two late-stage trials but development will continue

Teva 

Teva and partner Active Biotech have said they will continue to develop multiple sclerosis (MS) candidate laquinimod, despite side effects seen in two late-stage trials.

The two companies halted treatment with higher doses of laquinimod in the CONCERTO and ARPEGGIO trials on the recommendation of an external monitoring committee, but will continue to study lower doses of the drug. 

Eight patients across the studies suffered cardiovascular side effects, all of whom were on higher doses of the orally-active immunomodulator therapy (1.2mg or 1.5mg per day), according to Teva. None of the cases was fatal, and there was no evidence of any events on the lower dose (0.6mg).

Teva and Active Biotech have been through the mill trying to bring laquinimod to market, which was rejected for approval in Europe in 2014 after the Committee for Medicinal Products for Human Use (CHMP) said it needed additional evidence of a clinical benefit.

Earlier, Teva reported disappointing results from a phase III trial of the drug in relapsing-remitting MS which showed it was unable to reduce the annual rate of relapse compared to placebo. The two companies have been working together on the drug since 2004.

Teva has been trying to bring an orally-active MS therapy to market alongside its long-established injectable therapy Copaxone (glatiramer acetate) - which made more than $4bn in sales last year but is now facing generic competition in the US from Sandoz/Momenta's Glatopa.

Moreover, Copaxone and other injectable MS treatments such as beta interferons have already been under pressure thanks to the emergence of a trio of new oral therapies - Biogen's Tecfidera (dimethyl glutamate), Novartis' Gilenya (fingolimod) and Sanofi's Aubagio (teriflunomide) - that have rapidly found favour with patients and doctors.

The CONCERTO trial will continue in patients with relapsing-remitting MS, as will ARPEGGIO in the more severe secondary-progressive form of the disease. Patients enrolled in the trials will be provided with an update to confirm re-consent for participation.

Article by
Phil Taylor

5th January 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera

Creative - Digital - Strategic: We call ourselves an interaction agency, which is why we use a “People First Approach”....

Latest intelligence

Leveraging HCP Transparency Insights to Drive Future Customer Investments
EFPIA’s disclosure requirements present an opportunity to assess strategy and effectiveness...
How did pharma use Twitter at #ASCO16?
Each year, ASCO’s Annual Meeting brings together 30,000 oncology professionals from around the world, here we explore the #ASCO16 hashtag and how pharma utilised the channel during this year's event....
WHITE PAPER: How to engage with HCPs more effectively
Shrinking budgets and limitations on the time HCPs can spend with sales reps is making traditional engagement methods more and more ineffective. So, in order to reach the unreachable, pharma...

Infographics